Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986263 in moderate to extensive hepatic fibrosis
NCT02227459Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2014
- Primary completion
- May 2016
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of ND-L02-s0201 in hepatic fibrosis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Number of participants with serious and non-serious adverse events at 24 weeks. Started Oct 2014; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on NCT02227459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227459.